ImmunityBio (IBRX) Non Operating Income (2014 - 2026)
ImmunityBio (IBRX) reported Non Operating Income of -$563.0 million for Q1 2026, down 1373063.41% year-over-year from N/an in Q1 2025, and down 33652.82% quarter-over-quarter from -$1.7 million in Q4 2025.
ImmunityBio (IBRX) Non Operating Income (2014 - 2026) Analysis & Trends
ImmunityBio (IBRX) has 13 years of Non Operating Income data on file, last reported at -$563.0 million in Q1 2026.
- Non Operating Income for Q1 2026 came in at -$563.0 million, down 1373063.41% year-over-year; the trailing twelve-month figure through Mar 2026 was -$565.1 million (down 809.76% YoY), and the FY2025 annual result was -$2.2 million, down 14393.33% from the prior year.
- Non Operating Income fell to -$563.0 million in Q1 2026 per IBRX's latest filing, from -$1.7 million in the prior quarter.
- Over five years, Non Operating Income peaked at $79.7 million in Q4 2024 and troughed at -$563.0 million in Q1 2026.
- A 5-year average of -$30.7 million and a median of -$71000.0 in 2023 frame the typical range for Non Operating Income.
- The sharpest annual moves came in 2024 and 2026: Non Operating Income jumped 112309.86% in 2024, then plunged 1373063.41% in 2026.
- A 5-year view of Non Operating Income shows it stood at -$923000.0 in 2022, then surged by 92.31% to -$71000.0 in 2023, then jumped by 112309.86% to $79.7 million in 2024, then tumbled by 102.09% to -$1.7 million in 2025, then slumped by 33652.82% to -$563.0 million in 2026.
- Business Quant data shows IBRX's Non Operating Income at -$563.0 million in Q1 2026, -$1.7 million in Q4 2025, and -$187000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Op. Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | 5.75 Mn |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | - |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | 444,000.00 |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | - |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | 9.35 Mn |
| 10 | ImmunityBio | 7.55 Bn | 7.17 Bn | 43.97 Mn | -563.00 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -563.00 Mn |
| Dec 31, 2025 | -1.67 Mn |
| Sep 30, 2025 | -187,000.00 |
| Jun 30, 2025 | -278,000.00 |
| Mar 31, 2025 | -41,000.00 |
| Dec 31, 2024 | 79.67 Mn |
| Sep 30, 2024 | 12,000.00 |
| Jun 30, 2024 | -17,000.00 |
| Mar 31, 2024 | -20,000.00 |
| Dec 31, 2023 | -71,000.00 |
| Sep 30, 2023 | -15.51 Mn |
| Jun 30, 2023 | -28,000.00 |
| Mar 31, 2023 | -5.00 Mn |
| Dec 31, 2022 | -923,000.00 |
| Sep 30, 2022 | 6,000.00 |
| Jun 30, 2022 | -15.21 Mn |
| Mar 31, 2022 | -4,000.00 |
| Dec 31, 2021 | -12.28 Mn |
| Sep 30, 2021 | -9.59 Mn |
| Jun 30, 2021 | -5.50 Mn |